Ovangen dosage

What Ovangen is

A short synthetic bioregulator peptide, studied in research on liver tissue and hepatic cell biology.

No mechanism can be described, because no chemical identity for a compound under this name was established. PubChem returned no compound record for "Ovangen", and the Medical Subject Headings vocabulary contains no entry for it ^2,3. Why the name resists identification Short-peptide "bioregulators" are commonly referred to by Russian trade names rather than by sequence, and transliteration of those names into Latin… How it works →

What the human evidence shows

How long did human studies run?

No human study durations are recorded for Ovangen.

Ovangen draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

2 mg5 mg10 mg

2 · Water added

1 mL2 mL3 mL5 mL

3 · Amount per draw

mcgmg

4 · Syringe

30u50u100u

Your mix

10 mg + 2 mL water = 5 mg/mL

10 units holds 0.5 mg (500 mcg)

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	20	—
1 mL	10	—
1.5 mL	6.667	—
2 mL	5	—
2.5 mL	4	—
3 mL	3.333	—
5 mL	2	—

Supplies and handling

• Lyophilized vial
  Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
• Sterile diluent
  The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
• Graduated syringes
  Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
• Alcohol prep pads
  For wiping vial stoppers before each puncture.
• Nitrile gloves
  Clean gloves for aseptic handling.
• Sharps container
  Puncture-resistant container for used needles.

Storage

Handling should follow the certificate of analysis and written documentation supplied with the specific lot; no stability or handling data specific to this compound were identified in the sources reviewed. Short lyophilised peptides are generally treated as hygroscopic, light-sensitive solids whose reconstituted solutions are chemically less stable than the dry material. Amiravo does not provide preparation, reconstitution or administration instructions.

• Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
• Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
• Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent

The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.

Shook the vial and it foamed

Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.

The solution is cloudy or has particles

Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.

The powder cake looks melted or shrunken before reconstitution

This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.

Liquid sprayed back when the needle was removed

Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status

Not approved by the FDA for any use; no human drug labeling matching this name was returned by the openFDA Drug Label API ^5.

United States (FDA)

There is no approved FDA application for any product under this name; an openFDA Drug Label API query returned no matching human drug labeling ^5. The name does not appear in any of the three categories of FDA's list of bulk drug substances nominated for use in compounding under section 503A of the FD&C Act, as updated 14 May 2026 ^6.

Sport (WADA)

Not named in the WADA 2026 Prohibited List ^7. This is hedged negative evidence, not a clearance. Section S0 of that list prohibits at all times "any pharmacological substance which is not currently approved by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use)", and states that the class "covers many different substances including but not limited to" its named examples; an unidentified research-only peptide would fall to be assessed under that wording ^7.

Status varies by country and changes over time. How we describe regulatory status.

Ovangen compared with related compounds

Frequently asked questions

References

1. PubMed query for "ovangen" (0 records; the term was not recognised and no query translation was applied) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026
2. MeSH / NCBI Entrez query for "ovangen" (0 records) Medical Subject Headings, U.S. National Library of Medicine. 2026
3. PubChem compound name lookup for "Ovangen" (PUGREST.NotFound — no CID) PubChem, U.S. National Library of Medicine. 2026
4. ClinicalTrials.gov registry query for "ovangen" (0 studies returned) ClinicalTrials.gov (U.S. National Library of Medicine). 2026
5. openFDA Drug Label API query for "ovangen" (no approved human drug labeling returned) U.S. Food and Drug Administration / openFDA. 2026
6. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. 2026
7. World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026) World Anti-Doping Agency. 2026